Rankings/Yseop
Yseop logo

Yseop

WashedAI NativePrivateUpdated November 15, 2026

A pre-GenAI natural language generation platform that has not kept pace with the market.

Website
yseop.com
Founded
2007
CEO
Emmanuel Walckenaer
HQ
Paris, France
Stage
Private
Revenue
Not disclosed
Total Funding
$28M
Employees
11-50
Flag a data issue
AI Platforms
31.4Bluescore
Momentum42.1
Market MapEarly Stage
Rank change (7d)▼ 34

Executive Summary

Updated Nov 12, 2026

What they do

  • Generative AI that drafts regulatory documents for pharma and biotech companies
  • Automates clinical study reports, patient narratives, clinical summaries and CMC content
  • Works inside Microsoft Word and Veeva Vault, built on Amazon Bedrock

Why it matters

  • Customers reportedly include Eli Lilly, Novartis, GSK and AstraZeneca
  • Mixes symbolic AI, machine learning and LLMs so outputs are traceable and auditable
  • Says it generates over 27,000 reports a month, pointing to production use

Best fit

  • Top-20 pharma medical writing teams with heavy clinical study report workloads
  • Regulatory affairs groups that need faster submissions with outputs traceable to source data
  • Life sciences companies whose writers already work in Word and Veeva Vault

Watch-outs

  • Small vendor of roughly 140-150 staff facing IQVIA, Certara and Veeva
  • Funding is modest; latest deal was €10M from Claret Capital
  • Full one-click dossier automation is still a roadmap, not a shipped product

Products & Offerings

Yseop Copilot

Enterprise generative AI platform that drafts and checks clinical study reports, patient narratives, summaries and CMC documents inside Microsoft Word and Veeva Vault.

EnterpriseEnterpriseFlagship2023

One-Click Dossier

Planned eCTD-aligned workflow combining live data integration, AI content generation and adaptive templates to automate regulatory submission documents end to end.

PlatformEnterpriseEmerging2025

Financial reporting automation

Older natural language generation software that turns financial data into written reports for financial services clients.

EnterpriseEnterpriseLive
Analyst VerdictEvaluate

Updated Nov 12, 2026

Yseop is a credible specialist in regulatory and medical writing for life sciences, with real deployments at major pharma companies and a product that has been in production since 2023. It deserves a structured evaluation against Certara CoAuthor, Narrativa and Peer AI, run as a pilot on your own clinical study reports and narratives that tests source traceability and how reviewer edits are handled. Before committing, check its financial resilience and roadmap, given its small size and the AI products that larger platforms such as Veeva are building.

Signal Provenance

Latest observation date and source for each signal category

Signal CategoryLast UpdatedSource
Funding Signals
Last funding round, Funding stage
Nov 15, 2026Cited web research
Hiring Velocity
Headcount, Headcount growth
Nov 15, 2026Research agents (estimate)
Technical Output
Research papers, GitHub activity
Nov 13, 2026Hugging Face Hub + news feed + research agents
News Sentiment
News mentions, News sentiment
Nov 15, 2026Verified news feed
Partnership Signals
Enterprise partnerships, Distribution partners
Nov 15, 2026Research agents (estimate)
Revenue Indicators
ARR estimate, Revenue growth
Nov 15, 2026Research agents (estimate)
Leadership Signals
CEO tenure, Founder-led
Nov 15, 2026Research agents (estimate)
Competitive Position
Category rank, Market share
Nov 9, 2026Research agents (estimate)

Why this Bluescore?

6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology

Yseop scores below the AI250 median on every dimension. Its relative strength is Customer Adoption (5.2, 33rd percentile); its weakest area is Business Model & Revenue (2.5, 4th percentile).

In plain English

Yseop's Bluescore of 31.4 out of 100 is held back mostly by Business Model & Revenue, which scores 2.5 of 10 and sits at the 4th percentile among the AI250, with 15.8 points still left of its 21-point weight. Its strongest area is Customer Adoption at 5.2 of 10, though that only reaches the 33rd percentile, while Investment Momentum at 2.2 of 10 (12th percentile) also pulls it down. Business Model & Revenue and Product Depth each carry 21% weight and Product Depth scores 3.1 of 10, so improving Business Model & Revenue would move the overall score the most.

Written by AI from the scores below and checked against them; updated nightly.

D1 · Business Model & Revenue (21%)
2.5
+5.2 of 21 pts · 4th pct
D2 · Product Depth (21%)
3.1
+6.5 of 21 pts · 17th pct
D3 · Data & Model Moat (19%)
3.5
+6.6 of 19 pts · 22nd pct
D4 · Talent & Research (16%)
2.6
+4.1 of 16 pts · 26th pct
D5 · Customer Adoption (13%)
5.2
+6.7 of 13 pts · 33rd pct
D6 · Investment Momentum (10%)
2.2
+2.2 of 10 pts · 12th pct

Risks

Updated Nov 12, 2026

Larger rivals like Veeva, Certara and IQVIA could bundle competing AI writing tools
High
Limited funding and small headcount may restrict support, roadmap pace and long-term viability
Medium
Relies on Amazon Bedrock and third-party LLMs, creating model and cloud dependency
Medium
One-click dossier automation is still a roadmap; capabilities may lag the marketing
Medium
Focus on life sciences limits value for enterprises seeking a cross-industry platform
Low
Feedback